DRUG APPROVALS
October 16, 2019
Review of Selected NMEs 2019
Spotlighted are new molecular entities targeting solid tumors in patients with an NTRK gene fusion; acute lymphocytic leukemia; relapsed or refractory acute myeloid leukemia with FLT3 mutations; and locally advanced or multistatic breast cancer with a susceptible genetic alteration.
October 16, 2019
New Drug Review 2019
October 16, 2018
Review of Selected NMEs 2018
October 16, 2018
New Drug Review 2018
October 13, 2017
New Drug Review 2017
October 13, 2017
Review of Selected NMEs 2017
October 14, 2016
Review of Selected NMEs 2016
October 14, 2016
New Drug Review 2016
October 16, 2015
New Drug Review 2015
October 16, 2015
Review of Selected NMEs 2015
October 16, 2014
New Drug Review 2014
October 16, 2014
Review of Selected NMEs 2014
Copyright © 2000 - 2019 Jobson Medical Information LLC unless otherwise noted. All rights reserved. Reproduction in whole or in part without permission is prohibited.